跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,401 条关于
“Syndax Pharmaceutical”
全部
13,401
临床试验
587
药物
1,682
机构
2,165
资讯
8,967
2年前
Syndax Pharmaceuticals Announces Key Updates and 2024 Milestones
去年
Syndax Pharmaceuticals' Niktimvo Approved for cGVHD, Revumenib Awaits FDA Decision
去年
Syndax Pharmaceuticals' Revuforj Receives FDA Approval for Acute Leukemia with KMT2A Translocation
去年
FDA Grants Early Approval to Revuforj (revumenib) for Acute Leukemia Treatment, Boosting Syndax Pharmaceuticals
去年
FDA Approves Revuforj (axatilimab) for Relapsed or Refractory Chronic Graft-versus-Host Disease
去年
FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia
去年
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as New R&D Head and Chief Medical Officer
去年
Syndax Highlights FDA-Approved Therapies and Anticipated Milestones at J.P. Morgan Healthcare Conference
去年
FDA Approves Syndax's Revuforj (Revumenib) for Relapsed or Refractory Acute Leukemia with KMT2A Translocation
去年
FDA Approves Syndax's Revuforj (Revumenib) for Relapsed/Refractory KMT2A-Rearranged Acute Leukemia
第 1 页,共 897 页
上一页
下一页